Literature DB >> 24830515

Sex differences in stroke prevention in atrial fibrillation in French primary care. Results of the AFIGP (Atrial Fibrillation In General Practice) database.

Pierre Sabouret1, Leyla Depret-Bixio, François-Emery Cotte, Pierre Marie, Nabil Bedira, Patrick Blin.   

Abstract

BACKGROUND AND OBJECTIVES: Most of the French patients diagnosed with atrial fibrillation (AF) are managed by general practitioners (GPs). The objective was to evaluate stroke prevention in AF patients ahead of the arrival of the non vitamin K oral anticoagulant in France.
METHODS: A cross-sectional study using a French GPs database of all patients with a diagnosis of AF consulting their GP between July-2010 and June-2011. Multivariate analyses were used to identify determinants of prevention prescription.
RESULTS: Among 15,623 AF patients, 42.5 % were ≥75 years and 40.5 % women, 59.2 % had hypertension, 17.2 % diabetes, 11.4 % heart failure, 4.9 % stroke history. CHADS2 score was ≥1 for 83.1 % and ≥2 for 50.9 % of patients (CHA2DS2-VASc score ≥1 for 93.7 % and ≥2 for 82.3 %). Antithrombotic therapies were vitamin K antagonists (VKA) for 50.7 % of patients, followed by aspirin for 19.9 %, clopidogrel ± aspirin for 4.3 % and none for 25.1 %. For patients with CHADS2 scores ≥1, 73.3 % received an antithrombotic and for those with CHADS2 scores ≥2, 54.9 % were treated by a VKA. An age-stratified multivariate analysis showed that women had an odds ratio to be treated with VKA compared to 0.83 (95 % CI: 0.72-0.95) and 0.66 (95 % CI: 0.59-0.74) when aged <75 years and ≥75 years, respectively.
CONCLUSIONS: Most AF patients followed by French GPs required stroke prevention according to European guidelines, but many of them did not receive the recommended antithrombotic treatment. Women over 75 were a third less likely to be treated with recommended anticoagulants than men of similar age.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24830515     DOI: 10.1007/s00392-014-0726-y

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  35 in total

1.  Bias.

Authors:  Miguel Delgado-Rodríguez; Javier Llorca
Journal:  J Epidemiol Community Health       Date:  2004-08       Impact factor: 3.710

2.  Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study.

Authors:  Margaret C Fang; Daniel E Singer; Yuchiao Chang; Elaine M Hylek; Lori E Henault; Nancy G Jensvold; Alan S Go
Journal:  Circulation       Date:  2005-09-12       Impact factor: 29.690

3.  Preventing stroke in people with atrial fibrillation: a cross-sectional study.

Authors:  Simon de Lusignan; Jeremy van Vlymen; Nigel Hague; Lavanya Thana; Billy Dzregah; Tom Chan
Journal:  J Public Health (Oxf)       Date:  2004-12-08       Impact factor: 2.341

4.  Patients with atrial fibrillation in a primary care setting: Val-FAAP study.

Authors:  Vivencio Barrios; Alberto Calderón; Carlos Escobar; Mariano de la Figuera
Journal:  Rev Esp Cardiol (Engl Ed)       Date:  2011-11-04

5.  Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials.

Authors:  Mardi Gomberg-Maitland; Nanette K Wenger; Jan Feyzi; Maria Lengyel; Annabelle S Volgman; Palle Petersen; Lars Frison; Jonathan L Halperin
Journal:  Eur Heart J       Date:  2006-06-14       Impact factor: 29.983

6.  Differences and time trends in drug treatment of atrial fibrillation in men and women and doctors' adherence to warfarin therapy recommendations: a Swedish study of prescribed drugs in primary care in 2002 and 2007.

Authors:  Axel C Carlsson; Per Wändell; Kristina Sundquist; Sven-Erik Johansson; Jan Sundquist
Journal:  Eur J Clin Pharmacol       Date:  2012-06-10       Impact factor: 2.953

7.  Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation.

Authors:  B F Gage; M Boechler; A L Doggette; G Fortune; G C Flaker; M W Rich; M J Radford
Journal:  Stroke       Date:  2000-04       Impact factor: 7.914

8.  Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia.

Authors:  Richard-Olivier Fourcade; François Lacoin; Morgan Rouprêt; Alain Slama; Camille Le Fur; Emilie Michel; Axel Sitbon; François-Emery Cotté
Journal:  World J Urol       Date:  2011-09-03       Impact factor: 4.226

9.  Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis.

Authors:  F-E Cotté; P Fardellone; F Mercier; A-F Gaudin; C Roux
Journal:  Osteoporos Int       Date:  2009-05-21       Impact factor: 4.507

10.  Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry.

Authors:  Ajay K Kakkar; Iris Mueller; Jean-Pierre Bassand; David A Fitzmaurice; Samuel Z Goldhaber; Shinya Goto; Sylvia Haas; Werner Hacke; Gregory Y H Lip; Lorenzo G Mantovani; Alexander G G Turpie; Martin van Eickels; Frank Misselwitz; Sophie Rushton-Smith; Gloria Kayani; Peter Wilkinson; Freek W A Verheugt
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

View more
  10 in total

1.  Early results of first versus second generation Amplatzer occluders for left atrial appendage closure in patients with atrial fibrillation.

Authors:  Steffen Gloekler; Samera Shakir; Janosch Doblies; Ahmed A Khattab; Fabien Praz; Ênio Guerios; Dezsoe Koermendy; Stefan Stortecky; Thomas Pilgrim; Lutz Buellesfeld; Peter Wenaweser; Stephan Windecker; Aris Moschovitis; Milosz Jaguszewski; Ulf Landmesser; Fabian Nietlispach; Bernhard Meier
Journal:  Clin Res Cardiol       Date:  2015-03-04       Impact factor: 5.460

Review 2.  [Update on therapy of chronic heart failure. Innovations and studies from last year].

Authors:  Sebastian Ewen; Y Linicus; M Böhm
Journal:  Herz       Date:  2015-07-02       Impact factor: 1.443

3.  Utility estimations of health states of older Australian women with atrial fibrillation using SF-6D.

Authors:  Shazia S Abbas; Tazeen Majeed; Natasha Weaver; Balakrishnan R Nair; Peta M Forder; Julie E Byles
Journal:  Qual Life Res       Date:  2021-02-07       Impact factor: 4.147

Review 4.  Atrial fibrillation and long-term sports practice: epidemiology and mechanisms.

Authors:  S Wernhart; M Halle
Journal:  Clin Res Cardiol       Date:  2014-12-25       Impact factor: 5.460

Review 5.  [Chronic heart failure : current guideline recommendations and innovations].

Authors:  S Ewen; F Mahfoud; M Böhm
Journal:  Internist (Berl)       Date:  2015-07       Impact factor: 0.743

6.  Pregnancy outcome after exposure to the novel oral anticoagulant rivaroxaban in women at suspected risk for thromboembolic events: a case series from the German Embryotox Pharmacovigilance Centre.

Authors:  M Hoeltzenbein; E Beck; K Meixner; C Schaefer; R Kreutz
Journal:  Clin Res Cardiol       Date:  2015-07-21       Impact factor: 5.460

7.  Prognosis in patients with atrial fibrillation and a presumed "temporary cause" in a community-based cohort study.

Authors:  Laurent Fauchier; Nicolas Clementy; Arnaud Bisson; Karim Stamboul; Fabrice Ivanes; Denis Angoulvant; Dominique Babuty; Gregory Y H Lip
Journal:  Clin Res Cardiol       Date:  2016-09-30       Impact factor: 5.460

8.  Cardioversion of atrial fibrillation or atrial flutter into sinus rhythm reduces nocturnal central respiratory events and unmasks obstructive sleep apnoea.

Authors:  Henrik Fox; Thomas Bitter; Dieter Horstkotte; Olaf Oldenburg
Journal:  Clin Res Cardiol       Date:  2015-11-09       Impact factor: 5.460

9.  Burden of stroke and other cardiovascular complications in patients with atrial fibrillation hospitalized in France.

Authors:  Francois-Emery Cotté; Gwendoline Chaize; Anne-Françoise Gaudin; Adeline Samson; Alexandre Vainchtock; Laurent Fauchier
Journal:  Europace       Date:  2015-12-30       Impact factor: 5.214

10.  Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database.

Authors:  Bruno Detournay; Serge Halimi; Julien Robert; Céline Deschaseaux; Sylvie Dejager
Journal:  Vasc Health Risk Manag       Date:  2015-07-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.